I’ve spent years obsessing over the butyrate-to-acetate ratio in the aging colon, working under the assumption that a drop in production drives the loss of barrier integrity. But honestly, the math isn’t holding up. We’re seeing elderly cohorts with perfectly preserved microbial diversity who still show clear signs of metabolic endotoxemia. If the producers are there and the precursors are available, why does the signaling fail?

I suspect we’re suffering from a spatial resolution bias. We measure fecal SCFA concentrations and assume they reflect what’s happening at the luminal interface, completely ignoring the mucus-layer diffusion barriers that thicken or become increasingly hydrophobic as we age. It’s possible the butyrate is being produced, just sequestered in the wrong physical compartment—trapped in an aging glycocalyx that prevents it from ever hitting G-protein-coupled receptors like GPR109A.

We need to reconcile the gap between "total load" and actual receptor engagement. My field keeps pushing for more fiber or exogenous supplementation, but if the real issue is structural resistance to transit, we’re just pouring water into a clogged pipe.

A few questions keep me up at night:

• Are we dealing with a loss of monocarboxylate transporters (MCTs) at the colonic epithelium, or is this a post-binding signaling decay?
• Does the pH-dependent ionization of butyrate shift in the aging lumen, effectively rendering it inert before it reaches the target cells?
• Is "butyrate deficiency" actually just a bystander effect of a mitochondrial bioenergetic crisis in the epithelial cells, leaving them unable to utilize what’s available?

I’m open to being wrong. If you have evidence that we're seeing an actual depletion of the taxa themselves rather than a failure of local flux, I want to see the metagenomic data. Let’s stop assuming supply is the bottleneck.